TICKERNOMICS Sign up
Last Update: 2024-03-28 02:16:05
Altamira Therapeutics Ltd. ( CYTO ) https://altamiratherapeutics.com
2.40USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Bermuda
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-90.06%
CYTO
SPY
32.74%
-99.82%
CYTO
SPY
92.93%
-99.91%
CYTO
SPY
224.41%
CYTO
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
18.69
24.98
1.04
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.96
12.57
-9.23
-130.75
0.00
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.5595
1101.95
-496.55
1.15
Other Earnings and Cash Flow Stats:
Altamira Therapeutics Ltd. ( CYTO ) Net Income TTM ($MM) is 0.00
Altamira Therapeutics Ltd. ( CYTO ) Operating Income TTM ($MM) is 0.00
Altamira Therapeutics Ltd. ( CYTO ) Owners' Earnings Annual ($MM) is -23.31
Altamira Therapeutics Ltd. ( CYTO ) Current Price to Owners' Earnings ratio is -0.82
Altamira Therapeutics Ltd. ( CYTO ) EBITDA TTM ($MM) is 0.00
Altamira Therapeutics Ltd. ( CYTO ) EBITDA Margin is 0.00%
Capital Allocation:
Altamira Therapeutics Ltd. ( CYTO ) has paid 0.00 dividends per share and bought back -7.043281 million shares in the past 12 months
Altamira Therapeutics Ltd. ( CYTO ) has increased its debt by 6.3449835576216 million USD in the last 12 months
Capital Structure:
Altamira Therapeutics Ltd. ( CYTO ) Interest-bearing Debt ($MM) as of last quarter is 6
Altamira Therapeutics Ltd. ( CYTO ) Annual Working Capital Investments ($MM) are 4
Altamira Therapeutics Ltd. ( CYTO ) Book Value ($MM) as of last quarter is -3
Altamira Therapeutics Ltd. ( CYTO ) Debt/Capital as of last quarter is -314%
Other Balance Sheet Stats:
Altamira Therapeutics Ltd. ( CYTO ) has 0 million in cash on hand as of last quarter
Altamira Therapeutics Ltd. ( CYTO ) has 5 million of liabilities due within 12 months, and long term debt 3 as of last quarter
Altamira Therapeutics Ltd. ( CYTO ) has 7 common shares outstanding as of last quarter
Altamira Therapeutics Ltd. ( CYTO ) has 0 million USD of preferred stock value
Academic Scores:
Altamira Therapeutics Ltd. ( CYTO ) Altman Z-Score is -3.92 as of last quarter
Altamira Therapeutics Ltd. ( CYTO ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Altamira Therapeutics Ltd. ( CYTO ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Altamira Therapeutics Ltd. ( CYTO ) for the amount of $ on
0.65% of Altamira Therapeutics Ltd. ( CYTO ) is held by insiders, and 11.18% is held by institutions
Altamira Therapeutics Ltd. ( CYTO ) went public on 2014-08-06
Other Altamira Therapeutics Ltd. ( CYTO ) financial metrics:
FCF:-20.44
Unlevered Free Cash Flow:3.03
EPS:0.00
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:0.00
Beta:1.15
Buffet's Owners Earnings:-23.31
Price to Owner's Earnings:-0.82
About Altamira Therapeutics Ltd. ( CYTO ) :
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton, Bermuda.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.